Clinical Trial: Pharmacokinetics of Huperzine A Oral Solution in Healthy Participants

U.S., Aug. 26 -- ClinicalTrials.gov registry received information related to the study (NCT07784335) titled 'Pharmacokinetics of Huperzine A Oral Solution in Healthy Participants' on Aug. 13.

Brief Summary: In this study, 4 dose groups are planned: Group 1 (0.22 mg, QD), Group 2 (0.22 mg, BID), Group 3 (0.44 mg, QD), and Group 4 (0.44 mg, BID). Ten healthy study participants will be enrolled in each dose group, and randomized to the investigational drug group or the placebo group in a 4:1 ratio (i.e., 8 study participants in the investigational drug group and 2 study participants in the placebo group). An appropriate gender ratio will be ensured within each dose group.

Study Start Date: Aug. 25

Study Type: INTERVENTIONAL

Condition: Hea...